Published in

Newlands Press, Future Medicinal Chemistry, 18(5), p. 2175-2183, 2013

DOI: 10.4155/fmc.13.179

Links

Tools

Export citation

Search in Google Scholar

Pharmaceutical implications of helix length control in helix-mediated protein–protein interactions

Journal article published in 2013 by Lech-Gustav Milroy, Luc Brunsveld ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The most abundant protein secondary structure in nature – the α-helix – is frequently found at protein interfaces, making it an important lead structure for the design of small-molecule modulators of protein–protein interactions (PPIs). Nature’s ability to precisely control the length of α-helices, especially in the context of helix-mediated PPIs, is key to ensuring the optimal interaction of protein partners. By extension, precise control over the length of α-helix mimetics is necessary to ensure optimal disruption of α-helix-mediated PPIs. This article will highlight the emerging importance of helix length control in the context of helix-mediated PPIs through a discussion of the contemporary chemical approaches to identifying novel helix mimetic inhibitors, including all-hydrocarbon stapling, hydrogen bond surrogates and optimized peptides emerging from in vitro screening methods. A current update on the therapeutic status of the different approaches is provided, as well as indications as to their long-term potential.